BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

UK Hospital is the First in Europe to Place BiO2 Medical, Inc.'s Combined Triple Lumen CVC/IVC Filter, Known as the Angel™ Catheter, in a Critically Ill Patient to Protect From Life-Threatening Pulmonary Embolism


3/12/2013 9:40:00 AM

SAN ANTONIO, March 11, 2013/PRNewswire/ -- BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, is pleased to announce the first placement of their triple lumen Angel Catheter in the European Union. The Angel Catheter is a Nitinol (Nickel Titanium alloy), Inferior Vena Cava (IVC) filter, permanently attached to a central venous catheter (CVC) for the use of preventing Pulmonary Embolism (PE) in critically ill patients. Placed at the patient's bedside without the need for fluoroscopy, the Angel Catheter provides immediate protection from PE and is the first IVC filter to receive CE Mark approval for prophylactic indications.

In the UK more than 25,000 people die annually from hospital-related blood clots, with pulmonary embolism responsible for 10% of all deaths in hospital. In the United States, various sources state that anywhere between 200,000 and 300,000 people die annually from Pulmonary Emboli.

Dr. Carl Waldman, Consultant Anaesthetist & Intensive Care, Royal Berkshire NHS Trust, was quoted on BBC Radio as saying, "the new device can have a dramatic impact on most patients in intensive care who cannot be given anti-blood clotting medications."

He continued to say, "I think it has potential all over the world as a temporizing measure for critically ill patients.This new procedure can be carried out within an hour of the patient arriving in intensive care and takes only 15 minutes."

Additionally, research nurse Ellen Bowley, who was part of the team who placed the device in Mrs. Carter stated, "There is nothing like this, it is very exciting, and it could save thousands of lives."

According to Christopher E. Banas, BiO2 Medical's Chairman and Chief Executive Officer, "We believe that this innovative union of two relatively common medical devices, will provide physicians with an additional tool to protect a population of patients from hospital related PE, that are currently left with no other options. Dr. Angel and our team of engineers developed this technology to offer immediate Pulmonary Embolism protection for ICU patients during the critical unprotected window, while simultaneously allowing for lifesaving fluid and medication administration."

For more information regarding BiO2 Medical and the Angel Catheter, please visit www.bio2medical.com.

SOURCE BiO2 Medical, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES